SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing significant social media activity as investors debate its long-term viability, with many users weighing the potential for ecosystem-driven utility against concerns over its large supply and historical performance. The community remains deeply divided, featuring active discussions around meme coin market cycles, burn mechanisms, and comparisons to other speculative digital assets.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate whether the recent price decline represents a major accumulation opportunity or a value trap. While some community members remain bullish on its institutional utility and RWA potential, others are actively expressing frustration over its weak performance compared to the broader crypto market.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened community debate as investors weigh its long-term viability against broader crypto market volatility and shifting sentiment toward meme-based assets. While some holders maintain a bullish outlook tied to high-profile endorsements, others are expressing caution, frequently comparing it to emerging utility tokens and discussing potential support levels.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing heightened investor activity and positive momentum following a landmark agreement with the U.S. administration to lower drug prices in exchange for a significant tariff exemption and domestic manufacturing investments. The community is also reacting to strong pipeline updates, including promising Phase III results for baxdrostat and the transition of its listing to the NYSE, which have reinforced analyst confidence in the company's long-term revenue targets.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending as investors digest the implications of recent pipeline expansions and the impact of the upcoming Q2 earnings report on July 30, with active community discussion focusing on whether these moves signal a long-term growth strategy or a potential M&A event. Despite ongoing buyout speculation involving big pharma suitors, market participants remain focused on commercial momentum for Rezdiffra and the company's ability to maintain its leadership position in the MASH treatment sector.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending as investors capitalize on its newly formed partnership with NVIDIA and Amazon Web Services for the DOE-backed Project Prometheus, which aims to integrate AI into advanced nuclear reactor deployment. Community sentiment is heavily focused on the company's role in solving data center energy demand, with many tracking the stock as a long-term infrastructure play while managing volatility related to its pre-revenue status and capital requirements.

ProShares Trust II - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver is attracting intense community attention as traders debate whether the recent sharp pullback presents a prime buying opportunity or a signal of a broader commodity trend reversal. The conversation is largely split between those capitalizing on the extreme volatility for short-term gains and those maintaining long-term bullish convictions tied to industrial demand and potential supply constraints.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is currently drawing significant attention from investors as they weigh recent earnings results against broader consumer spending headwinds and evolving competitive pressures. The community is actively debating the company's long-term growth potential and turnaround strategies, with traders closely monitoring key support levels and options activity as the stock experiences increased volatility.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is seeing heightened investor attention as the community weighs strong growth from key immunology assets like Skyrizi and Rinvoq against potential market-share pressure from competitors like Johnson & Johnson's Tremfya. Investors are actively discussing the company's reliance on pipeline expansion, including strategic acquisitions and ongoing clinical trials, as it navigates the long-term impact of Humira's patent decline.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid community anticipation for the 'Clarity Act,' with discussions intensifying over whether legislative progress will finally unlock institutional utility for the token. While some investors see this as a critical inflection point for long-term adoption, others remain skeptical, focusing on the historical price stagnation and ongoing debate about XRP's role compared to other digital assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ABVC BioPharma (NASDAQ:ABVC) Trading Down 4.9% - Here's What Happened

ABVC BioPharma (NASDAQ:ABVC) Shares Down 4.9% - Here's What Happened...

ABVC BioPharma (NASDAQ:ABVC) Trading 1.6% Higher - What's Next?

ABVC BioPharma (NASDAQ:ABVC) Stock Price Up 1.6% - Time to Buy...

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

ABVC BioPharma Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.15
Prev Close	$1.20
Open	$1.20
Dividend Yield	0.00%
50-Day Moving Average	$1.35
Beta	1.00
Avg. Volume	144,575.03
PE Ratio	-2.95

52-Week High	$3.40
52-Week Low	$0.8801
Market Capitalization	$29.9M
EPS (Annual)	-$0.3933
Price to Book	2.75
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ABVCABVC BioPharma Inc

Latest ABVC News